Estrogen deprivation and estrogen receptor α antagonism decrease DSS colitis in female mice
Open Access
- 3 July 2024
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (4) , e1234
Abstract
The association of hormonal contraception with increased risk of inflammatory bowel disease (IBD) observed in females suggests involvement of ovarian hormones, such as estradiol, and the estrogen receptors in the progression of intestinal inflammation. Here, we investigated the effects of prophylactic SERM2 and estradiol supplementation in dextran sulfate sodium‐induced colitis using mice with intact ovaries and ovariectomized (OVX) female mice. We found that graded colitis score was threefold reduced in the OVX mice, compared to mice with intact ovaries. Estradiol supplementation, however, aggravated the colitis in OVX mice, increasing the colitis score to a similar level than what was observed in the intact mice. Further, we observed that immune infiltration and gene expression of inflammatory interleukins Il1b, Il6, and Il17a were up to 200‐fold increased in estradiol supplemented OVX colitis mice, while a mild but consistent decrease was observed by SERM2 treatment in intact animals. Additionally, cyclo‐oxygenase 2 induction was increased in the colon of colitis mice, in correlation with increased serum estradiol levels. Measured antagonist properties of SERM2, together with the other results presented here, indicates an exaggerating role of ERα signaling in colitis. Our results contribute to the knowledge of ovarian hormone effects in colitis and encourage further research on the potential use of ER antagonists in the colon, in order to alleviate inflammation.Keywords
Funding Information
- Svenska Kulturfonden (187699)
- Business Finland (253/31/2019, 473/31/2015)
- Victoriastiftelsen (20240472)
- Research Council of Finland (315139, 332582)
- Novo Nordisk Fonden (NNF21OC0068904)
This publication has 57 references indexed in Scilit:
- Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeNew England Journal of Medicine, 2003
- Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in MiceMolecular Endocrinology, 2003
- Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitisGut, 2002
- Tamoxifen and Cardiac Risk Factors in Healthy WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Substance P (Neurokinin-1) and Neurokinin A (Neurokinin-2) Receptor Gene and Protein Expression in the Healthy and Inflamed Human IntestineThe American Journal of Pathology, 2000
- Estrogen receptor β acts as a dominant regulator of estrogen signalingOncogene, 2000
- Estrogen receptor (ER) β, a modulator of ERα in the uterusProceedings of the National Academy of Sciences, 2000
- 17β-estradiol stimulates substance P receptor gene expressionMolecular and Cellular Endocrinology, 1997
- Induction of Substance P‐immunoreactivity by Estrogen in Neurons Containing Estrogen Receptors in the Anterovental Periventricular Nucleus of Female but not Male RatsJournal of Neuroendocrinology, 1994
- Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid ActionNew England Journal of Medicine, 1993